{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-082342","form_type":"8-K","ticker":"BCLI","cik":"0001137883","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","filed_at":"2023-07-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.225005+00:00","generated_at":"2026-06-13T06:14:26.662032+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"BrainStorm Cell Therapeutics announces $7.5M registered direct offering of common stock and warrants","bullets":["4,054,055 shares at $1.85 each, each with a warrant to purchase one share at $2.00 for five years.","Gross proceeds of ~$7.5M before placement agent fees and expenses.","Closing expected July 19, 2023; Maxim Group LLC is sole placement agent.","Offered under existing S-3 shelf registration statement (File No. 333-258640)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-082342","json":"https://secwatch.observer/filing/0001104659-23-082342.json","markdown":"https://secwatch.observer/filing/0001104659-23-082342.md","text":"https://secwatch.observer/filing/0001104659-23-082342.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923082342/0001104659-23-082342-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923082342/tm2321519d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T06:14:26.662032+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b00035f8d770055c74bb336d3b29fd33ec5f576","claim":"BRAINSTORM CELL THERAPEUTICS INC. entered into Purchase Agreement valued at approximately $7.5 million (effective 2023-07-17).","evidence_excerpt":"On July 17, 2023, Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchaser named therein (the “Purchaser”), pursuant to which the Company agreed to sell, in a public offering (the “Offering”), an aggregate of 4,054,055 shares of the Company’s common stock, par value $0.00005 per share (the “Common Stock”), together with accompanying warrants (the “Common Warrants”) to purchase 4,054,055 shares of Common Stock, at a purchase price of $1.85 per share and accompanying warrants for gross proceeds to the Company of approximately $7.5 million, before deducting fees payable to the placement agent and other estimated offering expenses payable by the Company.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923082342/0001104659-23-082342-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Value","value":"approximately $7.5 million"},{"label":"Effective","value":"2023-07-17"}],"fact_type":"material_agreement"},{"claim_id":"697558d4625add8d8d920c4525151d2846161c1b","claim":"BRAINSTORM CELL THERAPEUTICS INC. entered into Placement Agency Agreement with Maxim Group LLC (effective 2023-07-17).","evidence_excerpt":"the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC (“Maxim”) , pursuant to which Maxim agreed to serve as exclusive placement agent for the issuance and sale of the shares of Common Stock and accompanying Common Warrants.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923082342/0001104659-23-082342-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Maxim Group LLC"},{"label":"Effective","value":"2023-07-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}